|
|
|
28.12.25 - 15:48
|
The UK Health Care Disaster Is A Cautionary Tale For America′s Rising Class Of Armchair Socialists (ZeroHedge)
|
|
|
The UK Health Care Disaster Is A Cautionary Tale For America's Rising Class Of Armchair Socialists
Authored by Jonathan Turley,
The Washington Post shocked many of its Democratic readers this week by telling the truth about the growing disaster in the UK's National Health Service — a cautionary tale as a few Republicans plan to join Democrats to extend the failed Obamacare subsidies rather than reform our own broken health care system.
Socialism is in vogue in America. Various socialists are assuming greater power in the Democratic Party and mayors such as Zohran Mamdani (New York) and Katie Wilson (Seattle) are taking over the leadership of major cities.
I discuss the rising class of American socialists in my new book, Rage and the Republic: The Unfinished Story of the American Revolution. The young voters fueling this shift have never experienced life under socialism and have no memories of the meltdowns in prior such systems. As former socialist and communist countries move toward ca...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
26.12.25 - 03:48
|
China′s rising biotech clout on show in flurry of billion-dollar licensing deals (SCMP)
|
|
|
Chinese drugmakers have signed a late-year burst of out-licensing agreements with overseas partners, underlining China's growing role as a source of novel medicines as multinational pharma groups hunt for new assets.
Jacobio Pharmaceuticals said it expected to receive an upfront payment of US$100 million from AstraZeneca, according to a filing to the Hong Kong stock exchange on December 21.
The British-Swedish drugmaker was paying for exclusive rights to research, develop, register, manufacture......
|
|
|
26.12.25 - 03:00
|
Weight-loss therapy set to push pharma growth (Times of India)
|
|
|
India's obesity drug market is booming, poised for significant growth driven by rising lifestyle diseases and upcoming affordable generics. Experts anticipate wider access to GLP-1 medicines, accelerating innovation through AI, and a shift towards complex generics. This transformative phase promises improved patient outcomes and positions India as a key player in global healthcare advancements....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
23.12.25 - 21:27
|
Goldman′s Small-Cap Biotech Universe: The 2026 Catalyst Playbook For Investors (ZeroHedge)
|
|
|
Goldman's Small-Cap Biotech Universe: The 2026 Catalyst Playbook For Investors
There are just nine days left in the year, and this year has flown by.
We've delivered readers a steady stream of 2026 outlooks over the past few days and weeks, and next up is a year-ahead catalyst list from Goldman Sachs' small-cap biotech stock coverage.
Goldman analysts, led by Corinne Johnson, held their third "Year-Ahead" Catalyst Clinic, highlighting significant clinical catalysts for small-cap biotech companies (market caps under $3 billion) in their stock coverage universe.
Featured companies in the Catalyst Clinic included AbCellera Biologics, Allogene Therapeutics, Apogee Therapeutics, BioAge Labs, Entrada Therapeutics, Gossamer Bio, Gubra, Lyell Immunopharma, Recursion Pharmaceuticals, Sana Biotechnology, Sionna Therapeutics, Sera Prognostics, Tyra Biosciences, Viralgen, and Viridian Therapeutics.
Johnson said the sentiment from the event was mostly positive, with several names showing cl...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
